Beone Medicines Ltd's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Beone Medicines Ltd's ROI in the second quarter of 2026?
Beone Medicines Ltd achieved a return on average invested assets (ROI) of 10.32 % in its second quarter of 2026 a new company high.

ROI has improved compared to 9.14% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 102 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 933, from total ROI ranking in the first quarter of 2026 at 1592.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	64.46 %	48.29 %	29.85 %	9.99 %	-2.27 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	7,056	6,742	6,360	5,264	4,089
Return On Investment (TTM)	10.32 %	9.14 %	5.86 %	1.62 %	-4.6 %
ONC's Overall Ranking	# 933	# 1592	# 2187	# 2932	# 3202
Seq. Investment Change TTM	13.22 %	14.74 %	15.69 %	9.44 %	2.08 %
Seq. Net Income Change TTM	27.81 %	78.79 %	318.57 %	-	-
Net Income (TTM) in Millions	656	513	287	69	-178

ONC Company Profile >> Back to ONC Roi Comparisons >> See Annual ONC Return On Investment

Return On Investment ONC's Ranking
Within:	No.
Industry	# 40
Sector	# 103
Overall	# 933

Return On Investment Statistics
High	Average	Low
10.32 %	-28.73 %	-70.05 %
(Jun 30 2026)		(Jun 30 2017)

News about Beone Medicines Ltd Return on Investment ROI

Unveiling New Horizons in Cancer Therapy The Transformative Potential of Sonrotoclax and TEVIMBRA in Modern Oncolog...

November 27, 2025

Biopharmaceutical advances continue to transform the landscape of cancer treatment, offering new hope where traditional therapies have fallen short. In this article, we delve into the latest developments surrounding BeOne Medicines Ltd. s promising oncological agents, sonrotoclax and TEVIMBRA, two compounds set to redefine treatment protocols for various challenging cancer types. Sonrotoclax: A New Dawn in Relapsed or Refractory Mantle Cell LymphomaBeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), globally recognized for its commitment to oncology, has announced significant strides with its investigative agent sonrotoclax, a potent BCL-2 inhibitor. This announcement comes in the wake of new drug application (NDA) submissions to the U.S. Food and Drug Administration (FDA) for its use in treating relapsed or refractory (R/R) mantle cell lymphoma (MCL).

Financial Statements
Beone Medicines Ltd's II. Quarter Investments	$ 7,056 Millions	ONC's Balance sheet
Beone Medicines Ltd's II. Quarter Income	$ 237 Millions	Quarterly ONC's Income Statement
ONC's Income by Division		See ONC's Income by Division

ONC Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	6,360	3,706	3,995	4,911	7,046
Y / Y Investment Growth	71.61 %	-7.24 %	-18.64 %	-30.31 %	55.7 %
Net Income in Millions	287	-645	-882	-2,004	-1,413
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	4.51 %	-17.4 %	-22.07 %	-40.8 %	-20.06 %

Annual Roi Comment

In the fiscal year 2025 ROI improved to 4.51 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ONC's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ONC's Competitors
Subscribers only: Roi for Beone Medicines Ltd's Suppliers
Subscribers only: Return On Investment for ONC's Customers

Other Ratios
ONC's Roa	ONC's Inventory Turnover Ratio	ONC's Growth Rates	ONC's Dividend Statistics
	ONC's Profitability Ratios	ONC's Asset Turnover Ratio	ONC's Dividend Growth
ONC's Roe	ONC's Valuation Ratios	ONC's Financial Strength Ratios	ONC's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector	ROI
Protalix Biotherapeutics inc	25.72 %
Pro dex Inc	24.29 %
Innoviva Inc	23.33 %
Electromed Inc	23.18 %
Zevra Therapeutics Inc	22.90 %
Iradimed Corporation	22.57 %
Alnylam Pharmaceuticals Inc	22.10 %
Eton Pharmaceuticals Inc	21.31 %
Dexcom Inc	20.98 %
Healthcare Services Group Inc	20.93 %
Arcutis Biotherapeutics Inc	20.77 %
Chemed Corporation	20.13 %
Resmed Inc	20.01 %
Halozyme Therapeutics Inc	19.99 %
Vertex Pharmaceuticals Inc	19.97 %
Agilent Technologies inc	19.84 %
Illumina Inc	19.61 %
Puma Biotechnology Inc	19.60 %
United Therapeutics Corporation	19.53 %
Zoetis Inc	19.44 %
Krystal Biotech Inc	19.16 %
Carlisle Companies Incorporated	18.88 %
Neurocrine Biosciences Inc	17.51 %
Intuitive Surgical Inc	17.11 %
Theravance Biopharma inc	17.10 %
Standard Biotools Inc	16.38 %
Inspire Medical Systems inc	16.34 %
Aveanna Healthcare Holdings Inc	16.32 %
Harmony Biosciences Holdings inc	15.85 %
Entera Bio Ltd	15.84 %

Date modified: 2026-09-11T09:58:09+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.